Colombo, Sri Lanka – 13 August 2026 – Ceylon Hospitals PLC (CSE: DURD), a prominent player in Sri Lanka’s healthcare sector operating under the renowned Durdans brand, has announced its interim financial statements for the quarter ended 30th June 2026. The consolidated results reveal a strong performance, marked by significant revenue growth and an increase in profitability, underscoring the company’s resilience and strategic positioning in a dynamic market.
Key Financial Highlights for Q2 2026 (Consolidated)
For the three months ended 30th June 2026, Ceylon Hospitals PLC demonstrated a commendable financial trajectory:
- Revenue Growth: The Group recorded a consolidated revenue of Rs. 2,988.58 million, an impressive 8.54% increase compared to Rs. 2,753.48 million reported in the corresponding quarter of 2025. This growth highlights the sustained demand for its healthcare services.
- Gross Profit Expansion: Gross profit rose by 7.97% to Rs. 1,700.58 million in Q2 2026, up from Rs. 1,575.48 million in Q2 2025, reflecting efficient cost management alongside revenue gains.
- Profit After Tax (PAT): The Group’s profit after tax increased by 4.69% to Rs. 322.66 million from Rs. 308.21 million in the prior year’s quarter. Profit attributable to equity holders of the parent also saw a healthy increase of 6.02%, reaching Rs. 288.09 million compared to Rs. 271.72 million in Q2 2025.
- Earnings Per Share (EPS): Basic and diluted earnings per share improved to Rs. 1.72 for Q2 2026, up from Rs. 1.62 in Q2 2025, reflecting enhanced shareholder value. It is noted that comparative EPS figures have been retrospectively adjusted to reflect the share subdivision completed earlier in the year.
- Operational Performance: Results from operating activities stood at Rs. 427.15 million, an increase from Rs. 393.44 million in the same period last year.
Balance Sheet and Cash Flow Stability
As at 30th June 2026, Ceylon Hospitals PLC’s consolidated financial position remained robust:
- Total Assets: Total assets reached Rs. 18,815.97 million, compared to Rs. 18,346.07 million as at 30th June 2025, indicating continued asset base expansion.
- Total Equity: Total equity attributable to equity holders of the parent also grew to Rs. 11,992.58 million, up from Rs. 11,214.34 million in the previous year, demonstrating a solid capital structure.
- Operating Cash Flow: The Group reported a strong net cash flow from operating activities of Rs. 738.56 million for the quarter, significantly higher than Rs. 703.02 million recorded in Q2 2025, reflecting effective working capital management and operational efficiency.
Company-Level Performance
At the company level, Ceylon Hospitals PLC also posted strong results, with profit after tax surging by 20.14% to Rs. 276.02 million for the quarter ended 30th June 2026, up from Rs. 229.74 million in Q2 2025. This demonstrates healthy performance both at the consolidated and standalone entity levels.
The company also highlighted that the basic/diluted earnings per share calculations for the comparative periods have been adjusted retrospectively to reflect the share subdivision that occurred, with trading of subdivided shares recommencing on 5th March 2026. This ensures comparability and clarity for investors.
The interim condensed financial statements, though provisional and subject to audit, were authorized for issue by the Board of Directors on 11th August 2026, in compliance with LKAS 34 Interim Financial Reporting and the Companies Act No. 07 of 2007.
Ceylon Hospitals PLC’s consistent growth in both revenue and profitability, coupled with a healthy balance sheet and strong cash flows, positions the company favorably within Sri Lanka’s competitive healthcare landscape.
Source: Read original document